Therapeutic targeting of tumor suppressor genes Review uri icon

Overview

MeSH Major

  • Genes, Tumor Suppressor
  • Neoplasms

abstract

  • Carcinogenesis is a multistep process attributable to both gain-of-function mutations in oncogenes and loss-of-function mutations in tumor suppressor genes. Currently, most molecular targeted therapies are inhibitors of oncogenes, because inactivated tumor suppressor genes have proven harder to "drug." Nevertheless, in cancers, tumor suppressor genes undergo alteration more frequently than do oncogenes. In recent years, several promising strategies directed at tumor suppressor genes, or the pathways controlled by these genes, have emerged. Here, we describe advances in a number of different methodologies aimed at therapeutically targeting tumors driven by inactivated tumor suppressor genes.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4526158

Digital Object Identifier (DOI)

  • 10.1002/cncr.29140

PubMed ID

  • 25557041

Additional Document Info

start page

  • 1357

end page

  • 68

volume

  • 121

number

  • 9